Key Takeaways:
The FDA on Wednesday approved Pfizer Inc.'s Ibrance (palbociclib) in combination with trastuzumab and endocrine therapy for maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer, expanding the drug's label beyond its original indication.
"The PATINA trial results show that adding a CDK4/6 inhibitor to standard anti-HER2 and endocrine maintenance therapy meaningfully extends the time patients live without disease progression," Dr. Otto Metzger, lead investigator and breast cancer researcher at Dana-Farber Cancer Institute, said.
The approval, based on the Phase 3 PATINA trial enrolling 518 patients, showed a 24% reduction in the risk of disease progression or death, with a hazard ratio of 0.76. Extended follow-up data published in the New England Journal of Medicine in January showed median progression-free survival reached 44.3 months in the Ibrance group versus 29.1 months with standard therapy alone, a difference of 15.2 months. The estimated 48-month PFS rate was 46.5% compared with 38.3%.
Ibrance, a CDK4/6 inhibitor, was previously approved only for HR-positive, HER2-negative metastatic breast cancer. The label expansion opens a new patient population — those with both HR-positive and HER2-positive disease, a subgroup accounting for roughly 10% to 15% of all breast cancers that has historically faced limited maintenance options after induction therapy. Patients in the trial received 4 to 8 cycles of taxane plus trastuzumab, with or without pertuzumab, before randomization to maintenance therapy with Ibrance or standard care.
The recommended dosing is 125 milligrams orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles. Safety findings were consistent with Ibrance's established profile, with grade 3 neutropenia the most common adverse event. The prescribing information carries warnings for neutropenia, interstitial lung disease and pneumonitis, and embryo-fetal toxicity. The drug had previously received breakthrough therapy designation from the FDA for this use.
The approval positions Ibrance as the first CDK4/6 inhibitor cleared for the HER2-positive maintenance setting, potentially reshaping the treatment paradigm for this dual-receptor population. Overall survival data remain immature, and longer follow-up will determine whether the PFS benefit translates into a survival advantage. Pfizer shares traded little changed on the news. Investors will watch for updated peak sales estimates when the company reports second-quarter earnings on July 28.
This article is for informational purposes only and does not constitute investment advice.
